Skip to content

Clinical observation and new mechanism of triamcinolone acetonide in the treatment of hypertrophic scar

Clinical observation and new mechanism of triamcinolone acetonide in the treatment of hypertrophic scar

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17011482
Enrollment
Unknown
Registered
2017-05-24
Start date
2017-05-31
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar

Interventions

Case series:Nil

Sponsors

Department of Burns and Cutaneous Surgery, Xjing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18 and 65 years male and female; scar on any site of the body; duration of scar less than two years; scar given a local injection of triamcinolone acetonide for more than 3 months and softening and shrinking; Or patients who have not received topical treatment with triamcinolone acetonide and other drugs or lasers

Exclusion criteria

Exclusion criteria: The exclusion criteria were family history of scar; pregnancy; Patients having diseases like diabetes mellitus and congestive cardiac or lung diseases on the basis of history

Design outcomes

Primary

MeasureTime frame
the Vancouver Scar Scale;Histopathologic change;

Secondary

MeasureTime frame
Fibrosis factor;

Countries

China

Contacts

Public ContactLi Jun

The Fourth Military Medical University

xjburns@163.com+86 029 84775297

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026